NCT02079545 - Bioavailability and Pharmacokinetics Study of Sirukumab in Healthy Male Participants | Biotech Hunter

Enrollment

144

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Healthy

Interventions

DRUG

Sirukumab (IV infusion)

Participants will receive a single IV infusion of 100 mg sirukumab.

DRUG

Sirukumab (SC injection with PFS-U)

Participants will receive a single SC injection of 50 mg sirukumab with PFS-U.

DRUG

Sirukumab (SC injection with PFS-AI)

Participants will receive a single SC injection of 50 mg sirukumab with PFS-AI.

DRUG

Sirukumab (SC injection with PFS-U)

Participants will receive a single SC injection of 100 mg sirukumab with PFS-U.

DRUG

Sirukumab (SC injection with PFS-AI)

Participants will receive a single SC injection of 100 mg sirukumab with PFS-AI.

Trial Locations (2)

Tempe

Lincoln